SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

NeuroGenesis Bio Receives FDA Clearance for NG01 Expanded Access

The FDA cleared NeuroGenesis Bio to proceed with an expanded access program for NG01 in progressive multiple sclerosis.

Related stories